**Specifications Table**TableSubject area*Biology*More specific subject area*(Hepato)toxicogenomics*Type of data*Figure and Tables*How data was acquired*Illumina HiSeq. 2000 sequencer*Data format*Differentially methylated DNA regions/genes, pathways, statistical analysis*Experimental factors*Primary human hepatocytes (PHHs) were treated by valproic acid (VPA) at an incubation concentration of 15 mM for 5 days daily followed by a washout of 3 days*Experimental features*The treated samples were corrected for time-matched vehicle controls.The persistent changes were identified by determining DNA methylation similarities between samples of 5 days daily VPA-treatment and samples of 3 days washout upon the 5 days daily VPA-treatment*Data source location*Department of Toxicogenomics, Maastricht University, the Netherlands*Data accessibility*Methylated DNA Immuno-Precipitation -- sequencing (MeDIP-seq) raw data are available on ArrayExpress (accession number: E-MTAB-4437).*

**Value of the Data**•The data derived from primary human hepatocytes (PHHs) treated with valproic acid (VPA) as well as the data analysis approaches in this publication can serve as a benchmark to investigate the epigenetics effects of other hepatotoxic compounds, since the data show that Methylated DNA Immuno-Precipitation -- sequencing (MeDIP-seq) analysis is highly informative in disclosing novel mechanisms of VPA-induced toxicity in PHHs.•The investigation of persistent methylation changes in PHHs provides a new perspective for other studies related to the drug-induced steatosis or other forms of toxicity.•The listed gene *EP300* together with the neighbors, of the network analysis, can be used for the development of biomarker screening tools for the early detection of drug-induced steatosis or other forms of toxicity, also by using other cell types.

1. Data {#s0005}
=======

Methylated DNA Immuno-Precipitation -- sequencing (MeDIP-seq) analysis showed that the methylation of more than 6000 genes significantly changed after 5 days daily valproic acid (VPA)-treatment (3006 hypermethylated differentially methylated DNA regions (DMRs) and 3077 hypomethylated DMRs). 31 DMRs were persistently methylated after taking the compound away (11 hypomethylated DMRs and 20 hypermethylated DMRs). The names and functions of those persistent DMRs are shown in [Table 1](#t0005){ref-type="table"}. Furthermore, the 3006 hypermethylated and 3077 hypomethylated DMRs were classified into 119 significantly enriched pathways ([Table 2](#t0010){ref-type="table"}). The unique genes of all those 119 significantly enriched pathways, which have shown significant methylation changes in our data after 5 days daily VPA-treatment, formed a complex network module ([Fig. 1](#f0005){ref-type="fig"}A-B). The gene *EP300* has 33 neighbors ([Fig. 1](#f0005){ref-type="fig"}B-C) and the gene names, gene symbols, and fold changes (FCs) of those neighbors were shown in [Table 3](#t0015){ref-type="table"}. A more detailed description of those findings can be found in Wolters et al. [@bib1].Fig. 1(A, B) Large molecular interaction network identified by ConsensusPathDB, consisting of 201 genes derived from differentially methylated regions in PHHs after 5 days daily VPA-treatment. (C) VPA-induced sub-molecular interaction network of the 33 neighbor-genes of gene 2033 (*EP300*) in PHHs identified by ConsensusPathDB. EntrezGene IDs of the 33 neighbour-genes as well as the Gene symbol, Gene Name and the FCs can be found in [Table 3](#t0015){ref-type="table"}. green = hypermethylation; red = hypomethylation; yellow = neighbors of the gene 2033 (*EP300*) of the large molecular interaction network. PHHs, primary human hepatocytes; VPA, valproic acid; FCs, fold changes.Fig. 1Table 1Names and functions of the 20 persistently hypermethylated DMRs annotated to 15 unique Entrez Genes (A) and the 11 hypomethylated DMRs annotated to 9 unique Entrez Genes (B) of the MEDIP-seq analysis after the exposure of PHHs for 5 days daily to VPA followed by 3 days washout. PHHs, primary human hepatocytes; VPA, valproic acid; DMRs, differentially methylated DNA regions.Table 1**A) 20 persistently hypermethylated DMRs annotated to 15 unique Entrez GenesEntrez Gene IDGene SymbolGene NameNCBI Gene Function**114ADCY8adenylate cyclase 8 (brain)membrane bound enzyme that catalyses the formation of cyclic AMP from ATP5099PCDH7protocadherin 7The gene product is an integral membrane protein that is thought to function in cell-cell recognition and adhesion7625ZNF74zinc finger protein 74--23078VWA8von Willebrand factor A domain containing 8--55591VEZTvezatin, adherens junctions transmembrane proteinThis gene encodes a transmembrane protein which has been localized to adherens junctions and shown to bind to myosin VIIA57521RPTORregulatory associated protein of MTOR, complex 1encodes a component of a signaling pathway that regulates cell growth in response to nutrient and insulin levels79755ZNF750zinc finger protein 750This gene encodes a protein with a nuclear localization site and a C2H2 zinc finger domain. Mutations in this gene have been associated with seborrhea-like dermatitis with psoriasiform elements.80757TMEM121transmembrane protein 121--114784CSMD2CUB and Sushi multiple domains 2--122706PSMB11proteasome (prosome, macropain) subunit, beta type, 11Proteasomes generate peptides that are presented by major histocompatibility complex (MHC) I molecules to other cells of the immune system.254827NAALADL2N-acetylated alpha-linked acidic dipeptidase-like 2--338707B4GALNT4beta-1,4-N-acetyl-galactosaminyl transferase 4--388228SBK1SH3 domain binding kinase 1--440073IQSEC. 3IQ motif and Sec. 7 domain 3--100507290ZNF865zinc finger protein 865--  **B) 11 persistently hypomethylated DMRs annotated to 9 unique Entrez GenesEntrez Gene IDGene SymbolGene NameNCBI Gene Function**290ANPEPalanyl (membrane) aminopeptidaseAminopeptidase N is located in the small-intestinal and renal microvillar membrane, and also in other plasma membranes. In the small intestine aminopeptidase N plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases.29982NRBF2nuclear receptor binding factor 2--136051ZNF786zinc finger protein 786--414763BMS1P18BMS1 ribosome biogenesis factor pseudogene 18--643955ZNF733Pzinc finger protein 733, pseudogene--646096CHEK2P2checkpoint kinase 2 pseudogene 2--647121EMBP1embigin pseudogene 1--100101266HAVCR1P1hepatitis A virus cellular receptor 1 pseudogene 1--101927554LINC01250long intergenic non-protein coding RNA 1250--Table 2The 'enriched pathway-based sets' from the HOMER annotated genes of the 3006 hypermethylated DMRs and the 3077 hypomethylated DMRs after the exposure of PHHs for 5 days daily to VPA. PHHs, primary human hepatocytes; VPA, valproic acid; DMRs, differentially methylated DNA regions.Table 2**Pathway nameSet sizeCandidates, containedp-valueq-valuePathway source**Developmental Biology586129 (22.0%)3.23E-108.02E-07ReactomeAxon guidance459101 (22.0%)3.06E-083.81E-05ReactomeWnt signaling pathway - Homo sapiens (human)14036 (25.7%)3.17E-050.0262KEGGAxon guidance - Homo sapiens (human)12733 (26.0%)5.33E-050.0331KEGGSignalling by NGF38676 (19.7%)9.86E-050.0447ReactomeSignaling by SCF-KIT26456 (21.2%)0.0001080.0447ReactomeHippo signaling pathway - Homo sapiens (human)15436 (23.4%)0.0002570.0914KEGGDiseases of signal transduction18040 (22.2%)0.0003730.097ReactomeRegulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)209 (45.0%)0.000440.097ReactomeOxytocin signaling pathway - Homo sapiens (human)15936 (22.6%)0.0004940.097KEGGBMP2 signaling TGF-beta MV5617 (30.4%)0.0005010.097INOHFc gamma R-mediated phagocytosis - Homo sapiens (human)9224 (26.1%)0.0005020.097KEGGeffects of calcineurin in keratinocyte differentiation137 (53.8%)0.0005080.097BioCartaNOTCH1 Intracellular Domain Regulates Transcription4715 (31.9%)0.0005870.104ReactomeCalcium signaling pathway - Homo sapiens (human)18039 (21.7%)0.0007410.118KEGGSignaling by ERBB426352 (19.8%)0.001070.118ReactomeSignaling by PDGF30158 (19.3%)0.00110.118ReactomeSignaling by FGFR327053 (19.6%)0.001140.118ReactomeSignaling by FGFR427053 (19.6%)0.001140.118ReactomeSignaling by FGFR127153 (19.6%)0.001250.118ReactomeExtrinsic Pathway of Fibrin Clot Formation54 (80.0%)0.001260.118ReactomeG alpha (12/13) signalling events7620 (26.3%)0.001270.118Reactomealk in cardiac myocytes2710 (37.0%)0.001340.118BioCartaTGF-beta super family signaling pathway canonical11527 (23.5%)0.001350.118INOHnuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells85 (62.5%)0.001450.118BioCartaSignaling by FGFR227353 (19.4%)0.001480.118ReactomeInterleukin-3, 5 and GM-CSF signaling21143 (20.4%)0.001520.118ReactomeDownstream signaling of activated FGFR226752 (19.5%)0.001520.118ReactomeDownstream signaling of activated FGFR126752 (19.5%)0.001520.118ReactomeDownstream signaling of activated FGFR326752 (19.5%)0.001520.118ReactomeDownstream signaling of activated FGFR426752 (19.5%)0.001520.118ReactomeSignaling by FGFR27453 (19.3%)0.001610.118ReactomeHypertrophic cardiomyopathy (HCM) - Homo sapiens (human)8321 (25.3%)0.001670.118KEGGSignaling by Insulin receptor26251 (19.5%)0.00170.118ReactomeAndrogen receptor signaling pathway8922 (24.7%)0.001810.118WikipathwaysSignaling by NOTCH17319 (26.0%)0.001910.118ReactomeEctoderm Differentiation14131 (22.0%)0.001940.118WikipathwaysSignaling by ERBB227753 (19.1%)0.002060.118ReactomeInterleukin-2 signaling20241 (20.3%)0.002090.118ReactomeHTLV-I infection - Homo sapiens (human)25950 (19.3%)0.002240.118KEGGArrhythmogenic Right Ventricular Cardiomyopathy7419 (25.7%)0.002270.118WikipathwaysArrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human)7419 (25.7%)0.002270.118KEGGConstitutive Signaling by NOTCH1 HD+PEST Domain Mutants5315 (28.3%)0.00230.118ReactomeConstitutive Signaling by NOTCH1 PEST Domain Mutants5315 (28.3%)0.00230.118ReactomeSignaling by NOTCH1 PEST Domain Mutants in Cancer5315 (28.3%)0.00230.118ReactomeSignaling by NOTCH1 HD+PEST Domain Mutants in Cancer5315 (28.3%)0.00230.118ReactomeSignaling by NOTCH1 in Cancer5315 (28.3%)0.00230.118ReactomePlatelet activation - Homo sapiens (human)13129 (22.1%)0.002390.118KEGGAdipogenesis13129 (22.1%)0.002390.118WikipathwaysDownstream signal transduction27953 (19.0%)0.002420.118ReactomeSignaling by EGFR29255 (18.8%)0.002460.118ReactomeRegulation of nuclear beta catenin signaling and target gene transcription8020 (25.0%)0.002480.118PIDValidated nuclear estrogen receptor alpha network6417 (26.6%)0.002570.118PIDNCAM signaling for neurite out-growth22344 (19.7%)0.00260.118ReactomeDownstream signaling events of B Cell Receptor (BCR)12027 (22.5%)0.00260.118ReactomeBMP signaling Dro3411 (32.4%)0.002750.122INOHSignaling by Leptin19339 (20.2%)0.002870.124ReactomeInactivation of Cdc42 and Rac95 (55.6%)0.002910.124ReactomeDAP12 signaling28253 (18.8%)0.003060.129ReactomeMesodermal Commitment Pathway7619 (25.0%)0.003140.129WikipathwaysInsulin receptor signalling cascade23846 (19.3%)0.003210.129Reactomeregulation of pgc-1a218 (38.1%)0.003320.129BioCartaEPH-ephrin mediated repulsion of cells3010 (33.3%)0.003320.129ReactomeRetinoic acid receptors-mediated signaling3010 (33.3%)0.003320.129PIDFoxO signaling pathway - Homo sapiens (human)13429 (21.6%)0.00340.13KEGGInterleukin receptor SHC signaling19539 (20.0%)0.003460.13ReactomeNGF signalling via TRKA from the plasma membrane31057 (18.4%)0.003610.133ReactomeNRAGE signals death through JNK4513 (28.9%)0.003630.133ReactomeConstitutive Signaling by Aberrant PI3K in Cancer6116 (26.2%)0.003890.14ReactomeAMPK signaling pathway - Homo sapiens (human)12427 (21.8%)0.004220.148KEGGMAPK1/MAPK3 signaling19138 (19.9%)0.004240.148ReactomeSignaling by VEGF27451 (18.6%)0.004440.149ReactomeWnt Signaling Pathway and Pluripotency10123 (22.8%)0.004450.149WikipathwaysVEGFR2 mediated cell proliferation19839 (19.7%)0.004550.149ReactomeFRS-mediated FGFR2 signaling18637 (19.9%)0.004750.149ReactomeFRS-mediated FGFR1 signaling18637 (19.9%)0.004750.149ReactomeFRS-mediated FGFR3 signaling18637 (19.9%)0.004750.149ReactomeFRS-mediated FGFR4 signaling18637 (19.9%)0.004750.149ReactomeDilated cardiomyopathy - Homo sapiens (human)9021 (23.3%)0.004750.149KEGGrepression of WNT target genes105 (50.0%)0.005190.16ReactomeMAPK family signaling cascades22543 (19.1%)0.005290.16ReactomeMAPK signaling pathway - Homo sapiens (human)25748 (18.7%)0.005290.16KEGGtranscription regulation by methyltransferase of carm1146 (42.9%)0.005560.16BioCartaNetrin-1 signaling3711 (29.7%)0.00570.16ReactomeIRS-related events triggered by IGF1R23945 (18.8%)0.005830.16ReactomeIGF1R signaling cascade23945 (18.8%)0.005830.16ReactomeSignaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)23945 (18.8%)0.005830.16ReactomeNeuronal System29153 (18.2%)0.005950.16ReactomeDAP12 interactions29854 (18.1%)0.006140.16ReactomeGastric acid secretion - Homo sapiens (human)7518 (24.0%)0.006310.16KEGGFatty acid, triacylglycerol, and ketone body metabolism9822 (22.4%)0.006370.16ReactomePIP3 activates AKT signaling9822 (22.4%)0.006370.16ReactomePI-3K cascade:FGFR29822 (22.4%)0.006370.16ReactomePI-3K cascade:FGFR19822 (22.4%)0.006370.16ReactomePI-3K cascade:FGFR39822 (22.4%)0.006370.16ReactomePI-3K cascade:FGFR49822 (22.4%)0.006370.16ReactomePI3K events in ERBB4 signaling9822 (22.4%)0.006370.16ReactomePI3K events in ERBB2 signaling9822 (22.4%)0.006370.16ReactomeVEGFA-VEGFR2 Pathway26649 (18.4%)0.006390.16ReactomeCollagen biosynthesis and modifying enzymes6416 (25.0%)0.006440.16ReactomeIRS-mediated signalling23544 (18.7%)0.007040.173ReactomeO-linked glycosylation10523 (21.9%)0.007310.173ReactomeRAF/MAP kinase cascade18536 (19.5%)0.007590.173ReactomeSHC1 events in EGFR signaling18536 (19.5%)0.007590.173ReactomeSOS-mediated signalling18536 (19.5%)0.007590.173ReactomeGRB2 events in EGFR signaling18536 (19.5%)0.007590.173ReactomeSHC1 events in ERBB2 signaling18536 (19.5%)0.007590.173ReactomeSHC1 events in ERBB4 signaling18536 (19.5%)0.007590.173ReactomeGRB2 events in ERBB2 signaling18536 (19.5%)0.007590.173ReactomeRegulation of Commissural axon pathfinding by Slit and Robo43 (75.0%)0.007840.175ReactomeFosphenytoin (Antiarrhythmic) Metabolism Pathway43 (75.0%)0.007840.175SMPDBEphrin B reverse signaling248 (33.3%)0.00840.186PIDSignaling by Interleukins27049 (18.1%)0.008510.186ReactomeTransport of organic anions115 (45.5%)0.008520.186ReactomeRho GTPase cycle12526 (20.8%)0.009140.194ReactomePI3K/AKT activation10122 (21.8%)0.009180.194ReactomeThyroid hormone signaling pathway - Homo sapiens (human)11925 (21.0%)0.00920.194KEGGSignaling by NOTCH10723 (21.5%)0.009230.194ReactomeCell death signalling via NRAGE, NRIF and NADE6115 (24.6%)0.00960.2Reactome[^1]Table 3Names and FCs of the 33 neighbors of the EntrezGene ID 2033 (see [Fig. 1](#f0005){ref-type="fig"}) after the exposure of PHHs for 5 days daily to VPA. PHHs, primary human hepatocytes; VPA, valproic acid; FCs, fold changes.Table 3**Entrez Gene IDGene SymbolGene NameMeDIP-seq FCsSteatosis-related pathway(s)**354KLK3kallikrein-related peptidase 31.9--595CCND1cyclin D12.1--864RUNX3runt-related transcription factor 32--          1026CDKN1Acyclin-dependent kinase inhibitor 1 A (p21, Cip1)-3.5AdipogenesisSignaling events mediated by HDAC Class III          1387CREBBPCREB binding protein-3.2Signaling events mediated by HDAC Class IIITranscriptional regulation of white adipocyte differentiationRegulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)Signaling events mediated by HDAC Class IFatty acid, triacylglycerol, and ketone body metabolism1488CTBP2C-terminal binding protein 2-3.9--1844DUSP2dual specificity phosphatase 22.4--1958EGR1early growth response 1-3.6--          2033EP300E1A binding protein p300-5.2Signaling events mediated by HDAC Class IIITranscriptional regulation of white adipocyte differentiationSignaling events mediated by HDAC Class I2309FOXO3forkhead box O32.2Signaling events mediated by HDAC Class III2353FOSFBJ murine osteosarcoma viral oncogene homolog-3.5--2626GATA4GATA binding protein 42.5Adipogenesis4088SMAD3SMAD family member 32.4Adipogenesis4205MEF2Amyocyte enhancer factor 2 A2.2Adipogenesis4772NFATC1nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 11.8--5594MAPK1mitogen-activated protein kinase 12.3--5914RARAretinoic acid receptor, alpha-3.8Adipogenesis6095RORARAR-related orphan receptor A-4Adipogenesis          6256RXRAretinoid X receptor, alpha-3.8AdipogenesisTranscriptional regulation of white adipocyte differentiationRegulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)Fatty acid, triacylglycerol, and ketone body metabolism6670SP3Sp3 transcription factor-4.1--6776STAT5Asignal transducer and activator of transcription 5 A2.2Adipogenesis6925TCF4transcription factor 4-4--6929TCF3transcription factor 32.1--6934TCF7L2transcription factor 7-like 2 (T-cell specific, HMG-box)-3.4--6938TCF12transcription factor 122.12--7026NR2F2nuclear receptor subfamily 2, group F, member 22.6--7161TP73tumor protein p732.5--9252RPS6KA5ribosomal protein S6 kinase, 90 kDa, polypeptide 5-3.9--93149314Kruppel-like factor 4 (gut)2.7--          9611NCOR1nuclear receptor corepressor 1-3.4AdipogenesisTranscriptional regulation of white adipocyte differentiationRegulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)Signaling events mediated by HDAC Class IFatty acid, triacylglycerol, and ketone body metabolism10365KLF2Kruppel-like factor 2-3.3Signaling events mediated by HDAC Class III23411SIRT1sirtuin 1-3.590427BMFBcl2 modifying facto2.2

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Cell culture and treatment {#s0015}
-------------------------------

Cryopreserved primary human hepatocytes (PHHs, Invitrogen) of 3 individuals (Hu8084, Hu4197 and Hu4227) were thawed for 1 minute at 37 °C in a water bath. Next, these PHHs were pooled in order to bypass inter-individual variability in susceptibility to toxicants and cultured in 6-well plates in a collagen sandwich [@bib2], according to the supplier\'s protocol (Invitrogen). After 3 days, the PHHs were daily exposed to 15 mM VPA or 1% EtOH (vehicle control) in culture medium for 5 days. Culture medium was changed daily thereby administering a new incubation concentration of VPA or EtOH to the cells. After the exposure period of 5 days, PHHs were lysed for DNA isolation. Another well of PHHs was maintained in culture for 3 consecutive days without VPA-treatment (called washout); the culture medium was again changed every day. All experiments were performed in biological triplicates.

2.2. DNA isolation {#s0020}
------------------

PHHs were collected in 500 μL of digestion buffer (1 mM EDTA; 50 mM Tris--HCl, pH 8.0; 5% SDS) and proteinase K (1 mg/ml) (Ambion). After incubation for 1 hour at 55 °C, the proteinase K was inactivated at 80 °C. RNAse A (400 μg/ml) (Qiagen) and 1% collagenase (Sigma) treatment was performed for 1 h at 37 °C. An equal amount of phenol-chloroform-isoamylalcohol (PCI; 25:24:1) (Sigma) was added and shaken manually for 5 minutes. After centrifugation, the upper phase was again treated with PCI until protein was no longer visible at the interphase. The upper phase was precipitated using 50 µL of 3 M NaAc pH 5.6 and 1250 µL of cold 100% ethanol. The DNA pellet was washed using cold 70% EtOH, dissolved in 50 µL of nuclease free water and quantified spectrophotometrically using the NanoDrop 1000 (Thermo Scientific, Waltham, MA). The total amount of DNA obtained was at least 10 µg of DNA, the 260/280 ratio laid between 1.7--1.9, and the 260/230 ratio was higher than 1.6.

2.3. MeDIP-seq protocol {#s0025}
-----------------------

MeDIP-seq was performed, with all the biological triplicates after DNA isolation, according to the protocol of Taiwo et al. [@bib3], with minor adjustments.

### 2.3.1. DNA fragmentation to a size of \~200 bp {#s0030}

For DNA fragmentation, 300 ng of isolated DNA were sonicated on the bioruptor (Diagenode) by using instrument settings of 15 cycles, each consisting of 30 seconds on/off periods. After fragmentation, the genomic DNA size range was assessed using an Agilent 2100 Bioanalyzer and high-sensitivity DNA chips (Agilent Technologies), according to the manufacturer\'s instructions.

### 2.3.2. Library preparation and size selection {#s0035}

Libraries were prepared using 300 ng of fragmented DNA (\~200 bp) and the NEBNext Ultra DNA Library Prep Kit for Illumina (NEB), according to the manufacturer\'s protocol.

### 2.3.3. MeDIP analysis {#s0040}

The purified adaptor-ligated DNAs were used for Methylated DNA Immuno-Precipitation (MeDIP), according to the manufacturer\'s instructions of the MagMeDIP kit (Diagenode) and IPure kit (Diagenode).

### 2.3.4. Quality control {#s0045}

Quantitative PCR (qPCR) was used for controlling DNA methylation enrichment. qPCR was performed by measuring the Ct-values of 1 µL of purified DNA sample and 24 µL of qPCR mixture (1 µL of provided primer pair (reverse and forward), 12.5 µL of SYBR Green PCR master mix and 10.5 µL water) using the temperature profile: 95 °C for 7 min, 40 cycles of 95 °C for 15 s. and 60 °C for 1 minute, followed by 1 minute 95 °C. The efficiency of MeDIP was calculated by performing qPCR and using the following formula: %(meDNA-IP/Total input) = 2\^\[(Ct(10%input)-3.32) -- Ct(meDNA-IP)\] × 100%. The efficiency for methylated DNA fragments was good (\>50%) for all samples. More interestingly, the efficiency for non-methylated DNA fragments was overall lower than 1.0%.

### 2.3.5. PCR amplification and size selection {#s0050}

PCR was used to amplify the MeDIP adaptor-ligated DNA fragments. In brief, 25 µL NEBNext High Fidelity 2x PCR Master mix (NEB), 1 µL of Index primer (NEB) that was used as a barcode for each sample, and 1 µL of Universal PCR primer (NEB) were added to 23 µL of the MeDIP adaptor ligated DNA fragments. PCR was performed by using the temperature profile: 98 °C for 30 s, 15 cycles of 98 °C for 10 s, 65 °C for 30 sec., and 72 °C for 30 s, followed by 5 minutes at 72 °C and hold on 4 °C as described before [@bib3].

Thereafter, PCR-amplified DNAs (libraries) were cleaned using Cleanup of PCR Amplification in the NEBNext Ultra DNA Library Prep Kit for Illumina (NEB). Fragmented DNA size and quality were checked using the Agilent 2100 Bioanalyzer and high-sensitivity DNA chips (Agilent Technologies). In addition, generated libraries were size-selected on a 2% TAE low melting point (LMP) agarose gel; fragments of 250--350 bp were excised and the MinElute Gel DNA extraction kit (Qiagen) was used to extract and purify the DNA libraries. Libraries were quantified on a Qubit fluorimeter (Invitrogen) by using the Qubit dsDNA HS Assay kit (Invitrogen). All kits and chips were used according to the manufacturer\'s protocol.

### 2.3.6. Sequencing {#s0055}

The 12 amplified libraries, each sample having its own index primer, were pooled at an equimolar concentration of 2 nM, based on Qubit measurements. Ten, 15, and 20 pM of the 2 nM stock solution were then loaded onto three separated channels of a 1.4 mm flow cell (Illumina) and cluster amplification was performed on a cBot (Illumina). Clusters were generated on cBot (Illumina) using the TruSeq® PE Cluster Kit V3, according to the manufacturer\'s instructions (Illumina), and the paired-end libraries were sequenced using 2 × 100 cycles TruSeq™ SBS Kit v3 paired-end by sequencing by synthesis (SBS) on the Illumina HiSeq. 2000. Base calling was performed by using Casava 1.8.2 (Illumina) and de-multiplexing by using bcl2fastq 1.8.4 (Illumina). Sequence reads were aligned against the human reference genome called UCSC hg19. This alignment produces FASTQ files for each barcoded library. MeDIP-seq raw data are available on ArrayExpress (accession number: E-MTAB-4437).

2.4. Data analysis {#s0060}
------------------

### 2.4.1. MeDIP-Seq analysis {#s0065}

FastQC was applied to check the quality of the 100 bp reads pairs of the 12 sequenced samples. Paired-end sequencing reads were aligned against hg19 using Bowtie2 software. The MEDIPS package (version 1.16.0, Bioconductor) was used for the analysis of the MeDIP-seq data [@bib4], [@bib5], [@bib6]. The default parameters described in the MEDIPS guideline (version 1.16.0) [@bib7] were applied to all data from individual chromosomes, including mitochondrial DNA (chrM). The dataset was divided into four different groups of triplicates: (1) Control MeDIP samples includes the sequencing data of PHHs daily exposed during 5 days to the control vehicle; (2) VPA-treated MeDIP samples includes the sequencing data of PHHs exposed for 5 days daily to VPA; (3) Control washout MeDIP samples contains the sample exposed for 5 days daily with the vehicle control followed by a washout-period of 3 days; and (4) VPA-treated followed by washout MeDIP samples includes the sequencing data of PHHs exposed treated daily by VPA for 5 days followed by a washout-period of 3 days. Statistical analysis was performed applying the default parameters of MEDIPS, using the edgeR module, an empirical analysis of digital gene expression data in R that uses Bayes estimation and exact tests based on the negative binomial distribution [@bib8]. Notably, raw count data was normalized using the weighted trimmed mean of M-values (TMM-normalization). Regions were considered significantly methylated if the edgeR.p-value was below 0.01 and if the number of reads, of a specific region, in one of the samples was higher than the mean of reads of all regions (the whole genome), which is the background correction. This p-value was derived from other studies performing MeDIP-seq analysis [@bib9], [@bib10], [@bib11].

Annotation of DMRs into different genomic locations was achieved by using the HOMER software Regions were merged if (1) the start of a region was consecutive to the end of the previous region and (2) if the HOMER annotations of these consecutive DMRs were the same. Significant selected DMRs lists and unique gene lists were uploaded onto VENNY [@bib12]. In this paper, the names and functions of the persistent genes are available in [Table 1](#t0005){ref-type="table"}.

### 2.4.2. Pathway analysis {#s0070}

ConsensusPathDB [@bib13] was used to identify and visualize the involvement of the unique genes in biological processes that have been derived from affected pathways, by selecting significant pathways with a p-value \< 0.01 from a gene enrichment analysis. In this paper, the significant pathways are available in [Table 2](#t0010){ref-type="table"}.

### 2.4.3. Network visualization {#s0075}

Methylated genes were then uploaded onto Cytoscape. The circular layout was selected and the network was analyzed as undirected. FCs were added and nodes were colored (green = hypermethylation (positive FCs) and red = hypomethylation (negative FCs)).

The first neighbors of methylated hub genes were selected by using the tool first neighbors of selected nodes in Cytoscape. Then, a sub-molecular induced epigenome network with its first neighbors was prepared in Cytoscape. In this publication, molecular interaction networks and a sub-molecular interaction network of the gene *EP300* is available in [Fig. 1](#f0005){ref-type="fig"}.

Furthermore, names, FCs, and presence of the gene in one or more steatosis related pathways of the 33 neighbors of EntrezGeneID 2033 (*EP300*) are available in [Table 3](#t0015){ref-type="table"}.
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[^1]: The steatosis related pathways were shown in red.
